Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats

Abstract

PurposeBenign prostatic hyperplasia (BPH) impacts quality of life in men by causing lower urinary tract symptoms. α1-Adrenoceptor (α1-AR) blockers improve lower urinary tract symptoms. We investigated the efficacy of add-on therapy with α1-AR blockers on BPH rats.MethodsRats in the drug-treated groups were orally administered each drug once a day for 30 days after orchiectomy. To induce BPH, rats were castrated and testosterone (20 mg/kg) was injected subcutaneously once per day for 30 days. Cystometry was conducted to measure voiding contraction pressure and the interval contraction time, immunohistochemistry was performed to measure c-Fos and nerve growth factor (NGF) expression in the neuronal voiding centers, and nicotinamide adenine dinucleotide phosphate-diaphorase histochemistry was used to measure nitric oxide synthase (NOS) expression.ResultsOrchiectomy and testosterone injection decreased voiding contraction pressure and the interval contraction time, suggesting BPH symptoms. Voiding contraction pressure and the interval contraction time were greater in the group that received the combination treatment (tamsulosin with naftopidil) than in the tamsulosin monotherapy or naftopidil monotherapy groups. c-Fos, NGF, and NOS expression in the neuronal voiding centers was enhanced by BPH induction. c-Fos, NGF, and NOS expression was suppressed by the combination treatment (tamsulosin with naftopidil) to a greater extent than was the case for tamsulosin monotherapy or naftopidil monotherapy.ConclusionsCombination therapy of tamsulosin and naftopidil showed greater efficacy for the treatment of BPH than tamsulosin monotherapy or naftopidil monotherapy; therefore, combination therapy can be considered as a novel therapeutic method for BPH.

Relationship Between Chronic Periodontitis and Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia

“…First, this cross-sectional study could not be used to infer causality. Second, we could not adjust genetics and inflammations components as risk factors, both of which are one of important risk factors [ 8 ]. Additionally, this study might have a potential selection bias because we used a single institutional data.…”

“…Benign prostatic hyperplasia (BPH) refers to voiding dysfunction resulting from prostate enlargement and bladder outlet obstruction [ 7 ]. BPH is caused by nonmalignant, unregulated growth of the prostate gland, and it is a major cause of lower urinary tract symptoms (LUTS) [ 8 ]. BPH is highly prevalent in older men, and the prevalence was 27.7% according to a community-based study [ 9 ].…”

Relaxant Activities of Extracts from Uvaria rufa Blume and Caesalpinia sappan L. on Excised Rat’s Prostate Strips

“…Since alpha-1 adrenoceptors play an essential role in controlling the function of smooth muscles in the prostate and lower urinary tract, one of the most effective agents used to treat BPH and urological symptoms is the α 1 -adrenoceptor antagonist (alpha-1 blocker). Previous investigation showed that alpha-1 blockers were able to relax isolated prostate contraction in mice [39][40] and rats [41]. Therefore, agents which are able to relax the tone of rodent prostate smooth muscles via the same mechanisms as found in the human prostate, may relieve BPH symptoms.…”

Evaluation of PTEN Inhibitor Following Spinal Cord Injury on Recovery of Voiding Efficiency and Motor Function Observed by Regeneration in Spinal Cord

“…The voiding function was evaluated by cystometry 18 days after the surgery, as previously described [15]. The rats were anesthetized with Zoletil 50 (10 mg/kg, intraperitoneally; Vibac Laboratories, Carros, France).…”

“…Immediately after the cystometry, experimental animals were sacrificed for tissue collection. Tissue preparations were performed as previously described [15,16]. The rats were anesthetized using Zoletil 50 (10 mg/kg, interperitoneally; Virbac Lab-oratories).…”